Wedbush Maintains Neutral on Praxis Precision Medicine, Raises Price Target to $48
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Laura Chico maintains a Neutral rating on Praxis Precision Medicine (NASDAQ:PRAX) and raises the price target from $40 to $48.
August 14, 2024 | 5:38 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Wedbush analyst Laura Chico maintains a Neutral rating on Praxis Precision Medicine (NASDAQ:PRAX) and raises the price target from $40 to $48.
The raised price target from $40 to $48 by a reputable analyst suggests a positive outlook for Praxis Precision Medicine, which could lead to a short-term increase in stock price despite the Neutral rating.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100